Cargando…
Janus Kinase Inhibitors and Cell Therapy
Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions. These therapies are also associated with inflammatory con...
Autores principales: | Assal, Amer, Mapara, Markus Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438227/ https://www.ncbi.nlm.nih.gov/pubmed/34531878 http://dx.doi.org/10.3389/fimmu.2021.740847 |
Ejemplares similares
-
Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023) -
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021) -
Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018) -
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
por: Quadri, Iman, et al.
Publicado: (2023) -
Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)